970
Index
Anaesthetic agents
continued
drug–drug interactions, 427
pharmacokinetics, 426
therapeutic actions and indications,
426
older adults, 417
Anagrelide, 755, 758, 758
Anakinra, 253–255, 264, 266
Analgesic, 240, 241
Anaphylactic reaction, 33, 34
Anaplasia, 190
Anastrazole, 212, 213
Andostenedione, 962
Androgens, 627, 628–631
adverse effects, 630
androgenic effects, 627, 630
care considerations, 630–631
contraindications and cautions, 630
drug–laboratory test interferences, 630
pharmacokinetics, 629
therapeutic actions and indications, 629
Angelica, 962
Angina, 715
antianginal agents.
See
Antianginal
agents
handling an attack, 720–722
Angina pectoris, 713, 715
Angiogenesis, 190, 191
Angiotensin-converting-enzyme (ACE)
inhibitors, 657, 662–665, 668–669
adverse effects, 668
care considerations, 668–669
contraindications and cautions, 668
drug–drug interactions, 668
drug–food interactions, 668
pharmacokinetics, 668
therapeutic actions and indications,
662–663
Angiotensin II-receptor blockers, 665,
669–671
adverse effects, 669–670
angiotensin II-receptor, 657, 669
care considerations, 670–671
contraindications and indications, 669
drug–drug interactions, 670
pharmacokinetics, 669
therapeutic actions and indications, 669
Anidulafungin, 152, 154–155
Anise, 962
Anopheles
mosquito, 163, 164–165
Antacids, 896, 900, 904–906
adverse effects, 905
care considerations, 905–906
contraindications and cautions, 905
drug–drug interactions, 905
pharmacokinetics, 905
therapeutic actions and indications,
904–905
Antagonists, 15, 17
Anterior pituitary, 512, 515, 516
hormones, drugs affecting, 521,
525–530
growth hormone agonists.
See
Growth
hormone agonists
growth hormone antagonists.
See
Growth hormone antagonists
Anthelmintic agents, 179–188
adults, 183
adverse effects, 186
care considerations, 186–187
children, 183
contraindications and cautions, 186
critical thinking scenario, 184–185
drug–drug interactions, 186
helminths, 179, 180
intestine-invading worm infections,
180–181
Ascaris
, 179, 180, 181
cestodes, 179, 180, 181
hookworm infections, 179, 180, 181
nematodes, 179, 180
pinworm infections, 179, 180
platyhelminths (flatworms), 179, 181
threadworm infestation, 180, 181
whipworm infections, 179, 180, 181
older adults, 183
pharmacokinetics, 185–186
therapeutic action and indications, 185
tissue-invading worm infections,
181–182
filariasis, 179, 181
schistosomiasis, 179, 181–182
trichinosis, 179, 181
Anthrax, 106, 107, 282
Anti Rh(D) immunoglobin, 286
Antianginal agents, 713–726
adults, 717
beta-adrenergic blockers, 716, 722–723
adverse effects, 723
care considerations, 723
contraindications and cautions, 723
drug–drug interactions, 723
pharmacokinetics, 722–723
therapeutic actions and indications,
722
calcium channel blockers, 714, 716,
724–725
adverse effects, 724
care considerations, 725
contraindications and cautions, 724
drug–drug interactions, 724–725
pharmacokinetics, 724
therapeutic actions and indications,
724
children, 717
coronary artery disease (CAD), 713,
714–715, 730–731
nitrates, 713, 714, 716, 717–720
adverse effects, 718–719
care considerations, 719–720
contraindications and cautions, 718
drug–drug interactions, 719
pharmacokinetics, 718
therapeutic actions and indications,
717–718
older adults, 717
potassium channel openers, 714, 716,
825–726
Antiarrhythmic agents, 696–711
adults, 701
antiarrhythmics, 696, 701
arrhythmias, 697–701
automaticity, 697
conductivity, 697
haemodynamics, 697–698
types, 698–699
care considerations, 708–709
children, 701
chronic antiarrhythmic therapy,
managing, 709–711
class I, 702–704
adverse effects, 704
contraindications and cautions, 702,
704
drug–drug interactions, 704
pharmacokinetics, 702
therapeutic actions and indications,
702
class II, 703, 704–705
adverse effects, 705
contraindications and cautions, 705
drug–drug interactions, 705
pharmacokinetics, 705
therapeutic actions and indications,
704–705
class III, 703, 706
adverse effects, 706
contraindications and cautions, 706
drug–drug interactions, 706
pharmacokinetics, 706
therapeutic actions and indications,
706
class IV, 703, 706–707
adverse effects, 707
contraindications and cautions, 707
drug–drug interactions, 707
pharmacokinetics, 707
therapeutic actions and indications,
706
older adults, 701
proarrhythmic, 696, 701
Antiarthritis agents, 240, 252–255
care considerations, 255
disease-modifying antirheumatic drugs,
253–255
gold compounds, 252–253
Antiasthmatics.
See
Bronchodilators/
antiasthmatics
Antibiotics, 90–123
adults, 93
adverse effects, 87
aminoglycosides, 90, 95–97
adverse effects, 96
care considerations, 96–97
contraindications and cautions, 95–96
drug–drug interactions, 96
pharmacokinetics, 95
therapeutic actions and indications, 95
antimycobacterials.
See
Antimycobacterials
antineoplastic, 205–208
adverse effects, 207
care considerations, 208
contraindications and cautions, 207
drug–drug interactions, 207
pharmacokinetics, 207
therapeutic actions and indications,
205
